

HIV-positive women attending cervical screening consultation
n=3090

Exclusions* n=92 (3.0%)

Eligible women
n=2998 (97.0%)

Normal VI†
n=2382
(79.4%)

Inflammatory lesions‡ n=290 (9.7%)
LTFU, n=105 (36.2%)
Positive VI, n= 23/185 (12.4%)

Positive VI
n=245 (8.2%)

Not evaluable
SCJ not visible
n=81 (2.7%)

HIV-positive women referred for colposcopic examination (n=349)
268 positive VI: 9.0% (95% CI 8.0-10.0)
230 positive with VIA: 7.7% (95% CI 6.7-8.6)
255 positive with VILI: 8.5% (95% CI 7.5-9.5)

132 histological confirmations
4.4% (95% CI 3.7-5.1)
CIN 1 (n=115), CIN 2/3 (n=14), ICC (n=3)

73 LTFU‡
20.9% (95% CI 16.7-25.2)

HIV-negative women attending cervical screening consultation
n=1118

Exclusions* n=70 (6.3%)

Eligible women
n=1048 (93.7%)

Normal VI†
n=922
(88.0%)

Inflammatory lesions‡ n=64 (6.1%)
LTFU, n=10 (15.6%)
Positive VI, n= 3/54 (5.5%)

Positive VI
n=38 (3.6%)

Not evaluable
SCJ not visible
n=24 (2.3%)

HIV-negative women referred for colposcopic examination (n=65)
41 positive VI: 3.9% (95% CI 2.7-5.1)
20 positive with VIA: 1.9% (95% CI 1.1-2.7)
37 positive with VILI: 3.5% (95% CI 2.4-4.6)

20 histological confirmations
1.9% (95% CI 1.1-2.7)
CIN 1 (n=17), CIN 2/3 (n=0), ICC (n=3)

9 LTFU‡
13.8% (95% CI 5.5-22.2)